Novartis raises blockbuster drug forecasts to $18 billion as it seeks to prove growth can last
The drugmaker cited strong demand for its blockbuster drugs as it upgraded peak sales forecasts for multiple sclerosis, leukemia, and cholesterol medicines.
We haven't written up this one. CNBC has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.